A Multicenter National Prospective Study of Pregnancy and Neonatal Outcomes in Women With Inflammatory Bowel Disease
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Inflammatory Bowel Disease
- Sponsor
- University of California, San Francisco
- Enrollment
- 1500
- Locations
- 2
- Primary Endpoint
- Determine whether children born to women with IBD have higher rates of developmental delay compared to their age matched non-IBD peers, as measured by the Ages and Stages Questionnaire (ASQ-3) at ages 12, 24, 36, and 48 months
- Status
- Recruiting
- Last Updated
- 9 months ago
Overview
Brief Summary
A Multicenter National Prospective Study of Pregnancy and Neonatal Outcomes in Women with Inflammatory Bowel Disease study is being conducted at the University of California San Francisco and 30 other sites around the United States who are part of the CCFA Clinical Alliance. The aim of this study is to determine the effect of medication use and disease activity on the outcome of pregnancy among women with IBD up to 18 years from birth.
Detailed Description
All pregnant women with IBD diagnosis who are taking biologics medicines and immunosuppressants will be entered in the study.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Female patients with confirmed IBD diagnoses who are pregnant and taking immunosuppressants and/or biologic therapy
Exclusion Criteria
- •Pregnant female patients younger than 18 years of age
- •Confirmed multiple gestation
Outcomes
Primary Outcomes
Determine whether children born to women with IBD have higher rates of developmental delay compared to their age matched non-IBD peers, as measured by the Ages and Stages Questionnaire (ASQ-3) at ages 12, 24, 36, and 48 months
Time Frame: December 2014
Secondary Outcomes
- Determine whether the rate of any adverse pregnancy outcomes in a prospective national sample of women from the United States with IBD differ with respect to exposure to azathioprine/6MP or anti-TNF therapy(December 2014)